Last reviewed · How we verify
Amicar
At a glance
| Generic name | Amicar |
|---|---|
| Also known as | Aminocaproic Acid |
| Sponsor | Duke University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Efficacy of Amicar for Children Having Craniofacial Surgery (PHASE2)
- Intrawound Administration of Vancomycin in THA (NA)
- Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery (NA)
- A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery (PHASE4)
- Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation (PHASE4)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Intrawound Administration of Vancomycin in TKA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amicar CI brief — competitive landscape report
- Amicar updates RSS · CI watch RSS
- Duke University portfolio CI